Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13.